Mallinckrodt PLC (NYSE:MNK) will release its earnings data before the market opens on Tuesday, November 7th. Analysts expect Mallinckrodt PLC to post earnings of $1.82 per share for the quarter. Mallinckrodt PLC has set its FY17 guidance at $7.40-8.00 EPS.
Mallinckrodt PLC (NYSE:MNK) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.12. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The company had revenue of $824.50 million during the quarter, compared to analyst estimates of $829.56 million. During the same quarter in the previous year, the firm posted $2.03 EPS. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. On average, analysts expect Mallinckrodt PLC to post $7.38 EPS for the current fiscal year and $7.98 EPS for the next fiscal year.
Shares of Mallinckrodt PLC (MNK) traded up 2.53% on Tuesday, reaching $31.60. The company’s stock had a trading volume of 759,437 shares. The stock’s market capitalization is $3.07 billion. Mallinckrodt PLC has a 52 week low of $30.15 and a 52 week high of $68.12. The stock has a 50-day moving average of $34.37 and a 200 day moving average of $40.40.
A number of equities research analysts recently commented on MNK shares. Zacks Investment Research lowered Mallinckrodt PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Deutsche Bank AG set a $56.00 price target on Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $67.00 price target on Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Saturday, October 21st. Jefferies Group LLC restated a “buy” rating and set a $60.00 price target on shares of Mallinckrodt PLC in a research report on Friday, October 6th. Finally, Oppenheimer Holdings, Inc. set a $70.00 price target on Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $60.04.
In related news, insider Meredith B. Fischer purchased 1,280 shares of Mallinckrodt PLC stock in a transaction dated Wednesday, August 30th. The shares were acquired at an average cost of $39.63 per share, for a total transaction of $50,726.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.53% of the stock is owned by company insiders.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
What are top analysts saying about Mallinckrodt PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mallinckrodt PLC and related companies.